Top Story

Landmark prostate cancer screening trial may have misrepresented data

May 5, 2016

The rates of PSA screening reported in the control group of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial may have been inaccurately reported, according to a letter to the editor published in The New England Journal of Medicine.

As such, recent recommendations regarding the use of PSA — including recommendations against screening issued by the U.S. Preventive Services Task Force (USPSTF) in 2012 — may need to be reassessed, according to Jim C. Hu, MD, MPH, Ronald Lynch professor of urologic oncology at Weill Cornell Medicine and director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian Hospital.

Henry Ford Health System program director named Komen Scholar

May 5, 2016
Lisa A. Newman, MD, MPH, director of the breast cancer program at Henry Ford Health System, has been selected to serve as a Komen Scholar for a 3-year term.Komen…
Meeting News Coverage

ABIM to offer new MOC assessment options in January 2018

May 5, 2016
The American Board of Internal Medicine plans to offer a new Maintenance of Certification examination option in January 2018, according to a press release issued by the…
FDA NewsPerspective

FDA extends authority over e-cigarettes, cigars, hookah tobacco

May 5, 2016
The FDA today extended its regulatory authority over all tobacco products, including e-cigarettes, cigars and hookah tobacco, prohibiting retailers from selling these…
In the Journals

Low vitamin D increases risk for adverse pathology of localized prostate cancer

May 5, 2016
Vitamin D deficiency or insufficiency appeared associated with elevated risk for adverse pathology in men with localized prostate cancer who underwent radical…
More News Headlines »

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Meeting News Coverage

VIDEO: Copper depletion affects tumor microenvironment in patients at high risk for breast cancer recurrence

May 3, 2016
More »
CME Video

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Current Issues
View the Current Issue
HemOnc Today